A Phase 1, Randomized Clinical Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of The LEISH-F3 + GLA-SE Vaccine Compared To The LEISH-F3 Protein Alone In Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2015
At a glance
- Drugs LEISH-F3 peptide vaccine (Primary) ; Glycopyranosyl lipid adjuvant
- Indications Leishmaniasis
- Focus Adverse reactions
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Dec 2011 New trial record